• Alias: LBH-589
    • Hydroxamic acid that acts as a nonselective HDAC inhibitor
    • Currently in phase 1/2 clinical trials for hematologic malignancies
    • Recommended phase 2 dose: 20 mg/m2 IV weekly
    • Half-life: 16 hours
    • Common side effects: Nausea, fatigue, diarrhea, thrombocytopenia
    (Prince et al., 2007)
    Other topics in Targeted and Immunotherapy Agents